Trials / Completed
CompletedNCT03570957
A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patients
A Clinical Pharmacology Study of MT-2990 in Seasonal Allergic Rhinitis Patients (Single Dose Study)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 75 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 20 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to investigate the safety, tolerability, and pharmacokinetics of MT-2990 in patients with Japanese cedar pollen-induced seasonal allergic rhinitis (JC-SAR). Additional objective of the study is to investigate the efficacy and pharmacodynamics profile of MT-2990 in an environmental exposure chamber (EEC) on Day 8, 29, 57, and 85.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MT-2990 | MT-2990 solution for injection in vial |
| DRUG | Placebo | Placebo solution for injection in vial |
Timeline
- Start date
- 2018-07-17
- Primary completion
- 2018-12-27
- Completion
- 2018-12-27
- First posted
- 2018-06-27
- Last updated
- 2025-12-11
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03570957. Inclusion in this directory is not an endorsement.